IanFVA BRAND OF IONAFAIan Financial VisionAI-Driven. Independent. For Everyone.

Healthcare Valuations

Latest fair-value assessments and target prices by sector.

$15.21

NEOG Valuation Report 2026-10-07

Neogen Corporation navigates a complex landscape of growth and headwinds. Strategically transitioning from foundational strengthening to scalable growth, the company focuses on innovation – including a collaboration with Hinalea Imaging and a Petrifilm manufacturing shift – while addressing recent challenges. Despite 8.1% core revenue growth in Q1 2027, share price has declined due to an FDA warning regarding a recalled equine product, securities class action investigations, and broader macroeconomic pressures. While emphasizing operational efficiency and customer outcomes, Neogen faces risks related to working capital management, regulatory scrutiny, and supply chain vulnerabilities. Strategic divestitures aim to streamline operations and fund R&D, particularly in genomics and food safety. Valuation hinges on managing costs, executing strategic initiatives, and navigating macroeconomic factors, with current projections indicating potential near-term growth followed by stabilization and long-term, sustainable gains. The company’s financial health requires careful monitoring of debt levels, capital allocation, and the impact of ongoing legal and economic uncertainties.

$9.06

RZLT Valuation Report 2026-09-25

Rezolute, Inc. focuses on rare disease therapeutics, specifically hyperinsulinism, with its late-stage antibody, ersodetug, under regulatory review. Revenue relies on approval and serving a small patient population with premium pricing due to high unmet need. Despite potential for high price-to-sales multiples, the company currently faces substantial operating losses and negative cash flow, requiring ongoing external financing through equity or partnerships. Positive outcomes from ongoing clinical trials for both congenital and tumor-induced hyperinsulinism are critical to maximizing market reach. Analyst consensus is “Moderate Buy” with a $9.38 target, predicated on ersodetug’s success, but risks remain regarding regulatory hurdles, manufacturing, and competition. Financials reveal high working capital intensity and potential dilution from future fundraising. Macroeconomic factors, including modest GDP growth and inflationary pressures, present challenges, but Rezolute is strategically focused on securing approval and expanding trials. Management has shifted from aggressive growth to capital conservation following a trial setback, prioritizing ersodetug development. The company’s risk profile has evolved, emphasizing regulatory and financial risks, necessitating careful financial modeling. Rezolute aims to establish ersodetug as a universal therapy, but currently exhibits zero revenue and consistently negative net margins, relying heavily on external funding.

$70.34

COO Valuation Report 2026-09-10

The Cooper Companies (COO) generates revenue through vision care (CooperVision) and women’s health (CooperSurgical), with recent quarterly revenue of $1.066 billion, representing 1% organic growth. While Q3 2026 EPS exceeded expectations at $1.15, full-year guidance was lowered due to planned inventory reductions at CooperVision, causing a negative market reaction. The company opted against a sale or restructuring, instead authorizing a $3 billion share repurchase program. Analysis reveals increased options trading activity and a pressured valuation, despite strong results from a peer company. Management retains CooperSurgical, anticipating long-term growth in women’s health, but lacks immediate catalysts. Success hinges on navigating competitive pressures in the contact lens market, investing in R&D for CooperSurgical (genetic testing, fertility), and efficient working capital management. Recent strategic shifts prioritize capital returns over reinvestment, while risk factors include regulatory hurdles, supply chain vulnerabilities, and legal liabilities. Despite revenue growth, fluctuating gross and net margins, alongside volatile ROI and debt levels, necessitate careful monitoring. COO’s valuation currently averages $69.6 with a projected short-term CAGR of 30%, stabilizing to $68.21 over two years.

$68.27

BRKR Valuation Report 2026-09-10

Bruker Corporation is a diversified scientific instrument provider serving life science, materials science, and energy sectors, generating revenue through instrument sales, service contracts, and consumables. The company prioritizes R&D to maintain a competitive edge in technologically advanced markets, though profitability is impacted by high operating expenses. Recent strategic initiatives include collaborations with Luvata Materials and Atinary Technologies, focusing on fusion energy and AI-driven automation to diversify revenue and enhance efficiency. Investor engagement is increasing, with mixed institutional activity reflecting nuanced sentiment and a recent share price increase. Effective working capital management is crucial, given capital-intensive manufacturing. Future valuation will likely benchmark against peers using EBITDA multiples and P/E ratios. Over the past year, Bruker has shifted towards aggressive acquisitions and organizational restructuring, emphasizing organic growth and cost control. Risk factors include macroeconomic conditions, supply chain disruptions, and evolving regulatory landscapes. While revenue is growing, profitability remains volatile, requiring disciplined capital allocation and consistent execution to sustain long-term value creation. The company’s R&D intensity is high, and its current ratio is below industry average, indicating potential liquidity constraints.

$381.40

LH Valuation Report 2026-09-10

Labcorp is a diversified diagnostics provider focused on clinical laboratory services, generating revenue through testing volume, complexity, and client base (IDNs, physicians, pharma, patients). Revenue relies on negotiated reimbursement rates, demanding cost control. Strategic priorities include expanding clinical trial services via acquisitions like MLM Medical Labs to capitalize on the growing CRO market and investing in digital infrastructure to streamline trials. The company is also advancing precision medicine with offerings like the Elecsys® pTau-217 Alzheimer’s test. Recent financial performance shows growth supported by acquisitions, though shares are highly valued. Management has shifted towards aggressive cost management and capital allocation over the past four quarters. While facing macroeconomic headwinds – stable GDP but unchanged unemployment, and inflationary pressures – Labcorp aims to leverage secular trends in diagnostics. Key challenges include reimbursement pressures, operating costs, and integrating acquisitions. The company demonstrates improving, but volatile, financial metrics, requiring sustained earnings growth to justify valuation and careful monitoring of working capital.

$4.02

QTRX Valuation Report 2026-09-10

Quanterix Corporation is transitioning from a neurology-focused life science research tool provider to a diversified diagnostics company, highlighted by the Akoya Biosciences acquisition. While recent revenue ($32.9M in Q2 2026) fell short of expectations due to macroeconomic headwinds and internal execution issues, the company is strategically pivoting towards clinical diagnostics, particularly Alzheimer’s disease testing, and restructuring its commercial organization. Key to this is leveraging its Simoa platform for sensitive biomarker detection. Financial performance reveals a complex picture: fluctuating revenue, negative net margins despite increasing gross margins, and a reliance on acquisitions impacting cash flow. BlackRock’s recent investment ($15.7M stake) offers some validation. Successful integration of Akoya, achieving cash flow breakeven, and securing FDA approval for its Alzheimer’s test are critical for future valuation, which currently suggests moderate near-term growth potential ($2.65 to $4.02 in the next quarter) but longer-term stabilization around $3.40-$3.57. Monitoring working capital, managing costs, and navigating a challenging macroeconomic environment are essential for sustained profitability and shareholder value.

$16.22

INNV Valuation Report 2026-09-09

InnovAge provides comprehensive care to seniors through the PACE program, operating on capitated contracts with state and federal programs. Revenue is tied to participant numbers and per-member rates, requiring strong cost and quality management. Recent financial results show stabilization with increased adjusted EBITDA, though earnings per share missed estimates. Institutional investment from BlackRock and Algert Global signals cautious optimism. Geographic concentration creates regulatory and demographic risks, and expansion requires significant capital. The company faces scrutiny regarding reimbursement policies and must carefully manage working capital. Valuation should consider the unique risks of the PACE model alongside peer comparisons. Macroeconomic factors present a mixed landscape; stable GDP supports demand, but inflation pressures costs. Stable interest rates are beneficial, though credit market conditions could hinder future financing. InnovAge is shifting towards aggressive growth via acquisitions and technology, following a period of restructuring, with a focus on operational efficiency and margin expansion. While demonstrating improved financial flexibility, future expansion may require external financing.

$173.22

A Valuation Report 2026-08-27

Agilent Technologies demonstrates a diversified revenue model driven by recurring income from instruments, consumables, and service contracts, resulting in predictable earnings and stable gross margins. Recent Q3 2026 results showed 8.1% revenue growth to $1.88 billion, with EPS up 14% to $1.56, exceeding expectations. Management increased full-year guidance, projecting 6.5-7.5% revenue and 8.5% EPS growth, fueled by strength across all segments, particularly Life Sciences & Diagnostics which saw a 600 basis point operating margin increase. Institutional investor sentiment remains positive. Strategic initiatives focus on high-margin solutions in genomics, proteomics, and personalized medicine, supported by investments in liquid-based pharmacodiagnostics and next-generation sequencing. Financially, the company maintains a stable leverage ratio, actively manages debt maturity, and utilizes share repurchases and acquisitions to enhance shareholder value. A favorable macroeconomic outlook – stable GDP growth, moderate inflation, and predictable interest rates – supports continued performance, alongside a strategic shift towards operational efficiency and innovation. Recent financial management emphasizes cost reduction, customer experience, and long-term value creation, positioning Agilent for sustained growth despite competitive pressures and evolving market dynamics.

$5.97

RXRX Valuation Report 2026-08-23

Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI to discover and develop therapeutics across diverse diseases, including cancer and rare genetic disorders. Revenue currently stems from collaborations with Roche, Sanofi, and Merck, though the firm aims for proprietary drug sales. Recent financial performance reveals reliance on partnership revenue with a shortfall in year-over-year growth, necessitating cost discipline and extending its cash runway to early 2028. Its pipeline includes assets in both clinical and preclinical stages, with REC-4881 for familial adenomatous polyposis as the most advanced program. While strategic partnerships have secured over $500 million in non-dilutive funding, Q2 2026 earnings missed estimates. The company is shifting towards operational efficiency and prioritizing internal R&D, particularly in small molecule programs, while emphasizing its “agentic AI” platform. Valuation reflects high risk typical of the sector, dependent on clinical trial outcomes and securing further collaborations. Macroeconomic factors present challenges, but the company’s focus on capital discipline and AI-driven innovation positions it to manage external pressures, contingent on positive clinical data and a transition to proprietary revenue generation.

$17.85

NVAX Valuation Report 2026-08-20

Novavax is transitioning from direct vaccine sales to a licensing and royalty-based model due to declining pandemic demand, focusing on leveraging its Matrix-M adjuvant platform. Recent revenue contracted to $57 million, with a $53 million net loss, though loss per share beat estimates. The company anticipates sustained revenue via partnerships, notably with Sanofi for COVID-19 and influenza vaccines, and reduced expenses. Pipeline progress includes a C. difficile vaccine entering trials. Valuation of $716 million appears conservative given future revenue potential, though working capital intensity remains high. Macroeconomic factors like modest GDP growth and inflation present challenges, while the Sanofi partnership and Matrix-M’s broad applicability are key to future success. Over the past year, Novavax shifted capital allocation towards partnerships and cost reduction, prioritizing Matrix-M and operational efficiency. Risks include regulatory hurdles, supply chain fragility, and reliance on partnerships. The company’s strategic pivot requires successful execution of collaborations and pipeline development to achieve sustainable growth and enhance shareholder value.